Cell and gene therapies are transforming healthcare. Sponsors need to realize the potential now, forcing a rethink of monitoring to manage complexity.
Cell and gene therapies are transforming cancer treatment. Patients who would only live a few months on older treatments now have options that can significantly extend their lives. Sponsors are under pressure to realize the vast potential as quickly as possible, forcing them to rethink safety and efficacy monitoring to cope with the complexity of such therapies and their logistics.
In this whitepaper, we look at how the industry is rising to the challenge, focusing on how cell and gene therapies are radically improving health outcomes and the technologies and techniques that are facilitating their development. The paper covers:
Offered Free by: Cerba Research
See All Resources from: Cerba Research